IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN

S. Piepers; M.D. Jansen; E.A. Cats; N.M. van Sorge; L.H. van den Berg; W.L. van der Pol

doi:10.1016/j.jneuroim.2010.08.023

IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN

S. Piepers, M.D. Jansen, E.A. Cats, N.M. van Sorge, L.H. van den Berg, W.L. van der Pol

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The effects of intravenous immunoglobulins (IVIg) on anti-GM1 IgM titer and function, classical complement pathway activity, and antibody-complement interaction were investigated in 62 patients with multifocal motor neuropathy (MMN). In vitro, IVIg decreased complement deposition by anti-GM1 IgM antibodies. First IVIg treatment (2 g/kg) decreased C1q and C4 concentrations and classical pathway activity in serum. In sera from patients receiving IVIg maintenance therapy (0.4 g/kg) C4 concentrations and classical pathway activity were generally lower at higher IgG concentrations. The beneficial effects of IVIg in MMN may be explained by reduced antibody-mediated complement deposition in nerves amplified by a systemically attenuated classical pathway.

Original language	English
Pages (from-to)	256-262
Number of pages	7
Journal	Journal of Neuroimmunology
Volume	229
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2010.08.023
Publication status	Published - 15 Dec 2010

Keywords

Adult
Analysis of Variance
Case-Control Studies
Complement Pathway, Classical
Complement System Proteins
Enzyme-Linked Immunosorbent Assay
Female
G(M1) Ganglioside
Humans
Immunoglobulin M
Immunoglobulins, Intravenous
Male
Middle Aged
Motor Neuron Disease
Journal Article

Access to Document

10.1016/j.jneuroim.2010.08.023

Cite this

@article{cc57f302898c4cf5bbdb3512312523b0,

title = "IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN",

abstract = "The effects of intravenous immunoglobulins (IVIg) on anti-GM1 IgM titer and function, classical complement pathway activity, and antibody-complement interaction were investigated in 62 patients with multifocal motor neuropathy (MMN). In vitro, IVIg decreased complement deposition by anti-GM1 IgM antibodies. First IVIg treatment (2 g/kg) decreased C1q and C4 concentrations and classical pathway activity in serum. In sera from patients receiving IVIg maintenance therapy (0.4 g/kg) C4 concentrations and classical pathway activity were generally lower at higher IgG concentrations. The beneficial effects of IVIg in MMN may be explained by reduced antibody-mediated complement deposition in nerves amplified by a systemically attenuated classical pathway.",

keywords = "Adult, Analysis of Variance, Case-Control Studies, Complement Pathway, Classical, Complement System Proteins, Enzyme-Linked Immunosorbent Assay, Female, G(M1) Ganglioside, Humans, Immunoglobulin M, Immunoglobulins, Intravenous, Male, Middle Aged, Motor Neuron Disease, Journal Article",

author = "S. Piepers and M.D. Jansen and E.A. Cats and {van Sorge}, N.M. and {van den Berg}, L.H. and {van der Pol}, W.L.",

year = "2010",

month = dec,

day = "15",

doi = "10.1016/j.jneuroim.2010.08.023",

language = "English",

volume = "229",

pages = "256--262",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN

AU - Piepers, S.

AU - Jansen, M.D.

AU - Cats, E.A.

AU - van Sorge, N.M.

AU - van den Berg, L.H.

AU - van der Pol, W.L.

PY - 2010/12/15

Y1 - 2010/12/15

N2 - The effects of intravenous immunoglobulins (IVIg) on anti-GM1 IgM titer and function, classical complement pathway activity, and antibody-complement interaction were investigated in 62 patients with multifocal motor neuropathy (MMN). In vitro, IVIg decreased complement deposition by anti-GM1 IgM antibodies. First IVIg treatment (2 g/kg) decreased C1q and C4 concentrations and classical pathway activity in serum. In sera from patients receiving IVIg maintenance therapy (0.4 g/kg) C4 concentrations and classical pathway activity were generally lower at higher IgG concentrations. The beneficial effects of IVIg in MMN may be explained by reduced antibody-mediated complement deposition in nerves amplified by a systemically attenuated classical pathway.

AB - The effects of intravenous immunoglobulins (IVIg) on anti-GM1 IgM titer and function, classical complement pathway activity, and antibody-complement interaction were investigated in 62 patients with multifocal motor neuropathy (MMN). In vitro, IVIg decreased complement deposition by anti-GM1 IgM antibodies. First IVIg treatment (2 g/kg) decreased C1q and C4 concentrations and classical pathway activity in serum. In sera from patients receiving IVIg maintenance therapy (0.4 g/kg) C4 concentrations and classical pathway activity were generally lower at higher IgG concentrations. The beneficial effects of IVIg in MMN may be explained by reduced antibody-mediated complement deposition in nerves amplified by a systemically attenuated classical pathway.

KW - Adult

KW - Analysis of Variance

KW - Case-Control Studies

KW - Complement Pathway, Classical

KW - Complement System Proteins

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - G(M1) Ganglioside

KW - Humans

KW - Immunoglobulin M

KW - Immunoglobulins, Intravenous

KW - Male

KW - Middle Aged

KW - Motor Neuron Disease

KW - Journal Article

U2 - 10.1016/j.jneuroim.2010.08.023

DO - 10.1016/j.jneuroim.2010.08.023

M3 - Article

C2 - 20920831

SN - 0165-5728

VL - 229

SP - 256

EP - 262

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN

Abstract

Keywords

Access to Document

Fingerprint

Cite this